www.fdanews.com/articles/81494-clinical-data-on-factive-tablets-presented
CLINICAL DATA ON FACTIVE TABLETS PRESENTED
October 7, 2005
At the 43rd Annual Meeting of the Infectious Diseases Society of America, Oscient
Pharmaceuticals will present clinical data on its fluoroquinolone antibiotic,
Factive (gemifloxacin mesylate) tablets.
Data was obtained from a Phase III program studying Factive for the potential
treatment of acute bacterial sinusitis (ABS). The data are based on a meta-analysis
of four pooled Phase III studies, and examined the efficacy of Factive in treating
ABS in a specific sub-population of patients with allergic rhinitis. The retrospective
analysis determined that Factive, compared to the other drugs studied (cefuroxime
and trovafloxacin), was more effective in treating ABS in patients with allergic
rhinitis.